Yousif Capital Management LLC Decreases Stake in United Therapeutics Corporation $UTHR

Yousif Capital Management LLC decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 6.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 15,004 shares of the biotechnology company’s stock after selling 995 shares during the quarter. Yousif Capital Management LLC’s holdings in United Therapeutics were worth $6,290,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. CWM LLC lifted its holdings in United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after purchasing an additional 3,487 shares in the last quarter. AXQ Capital LP raised its position in shares of United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after buying an additional 33,662 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of United Therapeutics by 77.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock valued at $1,792,000 after buying an additional 2,655 shares during the period. Finally, State of Alaska Department of Revenue boosted its position in United Therapeutics by 17.0% during the second quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock worth $5,612,000 after acquiring an additional 2,840 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 3,517 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $495.36, for a total transaction of $1,742,181.12. Following the completion of the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $4,033,221.12. This represents a 30.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis W. Sullivan sold 5,950 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $512.13, for a total transaction of $3,047,173.50. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 599,664 shares of company stock worth $274,775,331. Company insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on UTHR. Oppenheimer boosted their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Bank of America lifted their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Stock Up 0.7%

UTHR stock opened at $513.99 on Thursday. The company has a market cap of $22.13 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 5.07 and a beta of 0.86. The business has a fifty day simple moving average of $468.27 and a 200-day simple moving average of $384.93. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.39 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.